Recent 8-K filings for CURLF

• November 10, 2026, 3:00 PM ET M&A materiality 0.65 positive item 8.01item 9.01

  Curaleaf secures all competition clearances for Aurora Cannabis bid; offer expires Dec 4

  Germany's Federal Ministry for Economic Affairs and Energy approved on Oct 20, 2026 Curaleaf's acquisition of 100% of voting rights in Aurora Europe, Aurora Deutschland and Aurora Produktions.

• November 5, 2026, 12:50 PM ET M&A materiality 0.65 neutral item 8.01item 9.01

  Curaleaf says enhanced Aurora bid stands; faults Aurora board for Organigram diligence access

  Curaleaf's enhanced premium offer, dated October 6, 2026, to buy all outstanding Aurora common shares remains outstanding; original circular dated August 18, 2026.

• November 3, 2026, 4:02 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Curaleaf Q3 2026 revenue $352.7M, up 10.9%; net loss $37.4M; adjusted EBITDA $77.6M

  Net revenue $352.7M vs $317.9M in Q3 2025 (+10.9%); sequentially up 3.6% from $340.1M. International revenue $59M (+28%), domestic +8%.

• November 2, 2026, 6:02 PM ET M&A materiality 0.40 positive item 7.01item 9.01

  Curaleaf acquires equity stake in Boone Town Provisions, expanding NJ footprint to four dispensaries

  Acquired an equity stake and certain operating rights in Boone Town Provisions, a dispensary at 677 Myrtle Ave., Boonton, NJ; deal value not disclosed.

• October 28, 2026, 2:59 PM ET M&A materiality 0.75 positive item 8.01item 9.01

  Curaleaf says ASC ruling doesn't change case for US$5.00/share Aurora bid at 86% premium

  Curaleaf's enhanced offer implies ~US$5.00 per Aurora share, an 86% premium to Aurora's unaffected VWAP of ~US$2.75; Aurora calls it a discount.

• October 19, 2026, 4:22 PM ET M&A materiality 0.72 neutral item 8.01item 9.01

  Curaleaf rebuts Aurora board rejection, cites 86% premium and 217% ex-cash premium for enhanced bid

  Curaleaf says its enhanced hostile offer for Aurora carries an 86% premium to Aurora's unaffected 30-day VWAP and 217% on an ex-cash basis; the bid is referenced at $5.00 per share.

• October 6, 2026, 1:47 PM ET M&A materiality 0.78 positive item 8.01item 9.01

  Curaleaf lifts Aurora Cannabis offer to US$5.00/share, an 86% premium; cap raised to US$6.00

  Enhanced Offer values Aurora at US$5.00 per share: 0.4013 Curaleaf subordinate voting shares plus US$1.00 cash, based on Curaleaf's C$14.21 close on October 2, 2026.

• October 6, 2026, 8:37 AM ET M&A materiality 0.78 positive item 8.01item 9.01

  Curaleaf raises Aurora Cannabis bid 25% to US$5.00/share; tender expiry extended to Dec 4, 2026

  Amended consideration is US$1.00 cash (up 33%) plus 0.4013 Curaleaf subordinate voting shares per Aurora share, for total implied value of US$5.00 per share.

• October 2, 2026, 6:26 PM ET leadership materiality 0.30 neutral item 5.02

  Curaleaf lifts CEO Boris Jordan's 2027 bonus target to 200% of salary, grants $15.4M in RSUs

  Compensation Committee increased Chairman and CEO Boris Jordan's target 2027 short-term incentive from 125% to 200% of his 2027 base salary.

• October 1, 2026, 5:28 PM ET other materiality 0.15 neutral item 7.01item 9.01

  Curaleaf sets Q3 2026 earnings release for Nov. 3 after market close

  Third quarter ended September 30, 2026 results will be reported after market close on Tuesday, November 3, 2026.

• October 1, 2026, 5:27 PM ET other material materiality 0.30 positive item 7.01item 9.01

  Curaleaf added to FTSE Canada All Cap Index effective Sept 18, 2026

  Curaleaf (TSX: CURA, OTCQX: CURLF) joins the FTSE Canada All Cap Index after the close of trading on Friday, September 18, 2026.

• September 16, 2026, 12:29 PM ET M&A materiality 1.00 positive item 8.01item 9.01

  Curaleaf urges Aurora shareholders to tender at $4.00/share, 45% premium

  Offer: 0.3463 Curaleaf shares + US$0.75 cash per Aurora share, implying US$4.00 vs US$2.76 pre-offer (45% premium).

• September 15, 2026, 3:56 PM ET M&A materiality 0.85 positive item 8.01item 9.01

  Curaleaf urges Aurora shareholders to tender; touts 45% premium, $4.00 offer

  Offer of 0.3463 Curaleaf shares + $0.75 cash per Aurora share implies $4.00 price, 45% premium to $2.76.

• September 14, 2026, 3:30 PM ET M&A materiality 0.80 positive item 8.01item 9.01

  Curaleaf asks Alberta regulator to halt Aurora's ATM share sales during US$4.00/share offer

  Filed application with Alberta Securities Commission to stop Aurora's ATM issuances during pending US$4.00/share offer.

• September 8, 2026, 5:08 PM ET M&A materiality 0.80 positive item 8.01item 9.01

  Curaleaf fact sheet defends 45% premium offer for Aurora, rebuts criticisms

  Offer represents 45% premium (~110% ex-cash); US$5.00 cap in 92nd percentile of Canadian M&A premiums.

• September 2, 2026, 1:15 PM ET M&A materiality 0.80 neutral item 8.01item 9.01

  Curaleaf defends 45% premium offer for Aurora, attacks Aurora's dilution and cash burn

  Curaleaf reaffirms hostile offer for Aurora, citing 45% premium (110% ex-cash) and $5 cap (82% premium to Aug 10 VWAP).

• August 24, 2026, 6:55 PM ET M&A materiality 0.90 positive item 8.01item 9.01

  Curaleaf rebuts Aurora's claims, cites 35% share decline and weak EBITDA

  Aurora shares fell ~35% over past year vs Curaleaf +56%; Curaleaf reiterates substantial premium offer.

• August 18, 2026, 9:16 AM ET M&A materiality 0.90 positive item 8.01item 9.01

  Curaleaf launches formal take-over bid for Aurora Cannabis at $4.00/share, 45% premium

  Offer: 0.3463 Curaleaf shares + US$0.75 cash per Aurora share, total ~US$4.00, 45% premium to unaffected price.

• August 12, 2026, 11:03 AM ET M&A materiality 0.90 positive item 8.01item 9.01

  Curaleaf launches hostile take-over bid for Aurora Cannabis at US$4.00/share, 45% premium

  Offer: 0.3463 Curaleaf shares + US$0.75 cash per Aurora share, total US$4.00; 45% premium to 30-day VWAP of US$2.75.

• August 5, 2026, 10:00 PM ET other materiality 0.00 neutral item 8.01item 9.01

  Curaleaf files 8-K with XBRL data only; no material event disclosed

  Filing contains only XBRL taxonomy references and context IDs, no narrative or press release.

• August 5, 2026, 9:51 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Curaleaf Q2 2026 revenue $340M (+10% YoY), net income $12.5M, adjusted EBITDA $70M

  Net revenue $340.1M, up 10% YoY from $310.6M; international revenue $51M (+26% YoY).

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.75 · Most common event m_and_a

15 positive 0 negative 6 neutral

source · CURLF on sec.gov